For patients with chronic heart failure (HFrEF or HFpEF), EECP improves exercise tolerance, eases shortness of breath, and helps your heart pump more efficiently, without surgery, without a new device, without side effects from another medication.
It means your heart isn’t pumping or relaxing efficiently enough to meet your body’s needs. The result is fluid backup, fatigue, and shortness of breath that gets worse with activity. EECP works on the underlying circulation problem, not just the symptoms.
Sudden severe shortness of breath, chest pain, or coughing up pink frothy sputum is a medical emergency. Call 911. This page is for stable, diagnosed heart failure.
Over 35 outpatient sessions, EECP increases venous return to the heart, lowers the workload it has to push against, and stimulates new collateral vessels. For HF patients, that translates into measurable gains in exercise tolerance and quality of life.
The PEECH trial, the landmark randomized study in HF, showed EECP patients walked significantly longer on the 6-minute walk test and improved their peak oxygen uptake on exercise testing. Real-world activity gets easier first.
A meaningful share of patients move from Class III (symptoms with mild activity) to Class II (symptoms only with significant activity). For someone who couldn’t walk to the mailbox, getting back to normal errands is life-changing.
Registry data on HF patients post-EECP shows reduced HF-related hospitalizations in the year following treatment. EECP works alongside your guideline-directed medical therapy, it doesn’t replace it.
EECP for heart failure has been studied in the landmark PEECH trial and tracked across thousands of patients in the International EECP Patient Registry (IEPR-2). Here’s what the published data actually shows.
Yes, patients with reduced EF (HFrEF) are exactly who the PEECH trial enrolled. The protocol was specifically studied in NYHA Class II–III patients with EF ≤ 35%. We screen carefully and coordinate with your cardiologist, but low EF alone is not a barrier, it’s the indication.
Yes. Smaller studies of HFpEF patients show improvements in diastolic function and exercise capacity after a standard 35-session course. HFpEF has fewer drug options than HFrEF, which makes non-drug therapies like EECP especially valuable. Coverage varies, we verify yours before you start.
No. EECP works alongside your guideline-directed medical therapy, beta-blockers, ACE/ARB/ARNI, MRAs, SGLT2 inhibitors, diuretics. Many patients find their meds work better when paired with EECP because circulation improves. Your cardiologist stays in charge of medication adjustments.
Medicare’s national coverage is for EECP in patients with angina (CCS Class III–IV) that persists despite optimal medical therapy. Many heart-failure patients also have qualifying angina and are covered on that basis. EECP for heart failure alone is currently considered investigational by Medicare and is not separately covered. Most Medicare Advantage and many commercial plans follow Medicare’s lead. We verify your specific coverage before you start, no surprises.
Pacemakers and ICDs are not a contraindication. The cuffs sit on your legs, not your chest, and the device timing actually helps EECP coordinate with your heartbeat. We confirm your device status during intake and adjust the protocol if needed.
EECP isn’t right for everyone, decompensated HF, severe aortic insufficiency, uncontrolled hypertension, certain arrhythmias, recent DVT, or significant peripheral arterial disease can disqualify you. We screen carefully before starting, and we’ll tell you honestly if it isn’t a fit, no fee, no follow-up unless you ask.
No surgery talk. No commitment. Just answers from the team that has helped 50,000+ patients regain energy, walk further, and feel like themselves again.
